Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, partly due to its high level of drug resistance. β-Catenin is critical for drug resistance in pancreatic cancer, which occurs through multiple mechanisms. Here, we observed that miR-33a targeted the 3′UTR of β-catenin, inducing apoptosis and inhibiting the growth of human pancreatic cancer cells. Moreover, gemcitabine (GEM) treatment enhanced β-catenin expression by reducing miR-33a expression in a dose-dependent manner. GEM-resistant MiaPaCa-2 res cells with a low level of miR-33a expression and high level of β-catenin expression adopted spindle-shaped morphologies, similar to their morphologies during the epithelial-to-mesenchymal transition (EMT), and their normal morphologies were restored by miR-33a overexpression. Furthermore, miR-33a downregulated β-catenin nuclear translocation, decreasing the transcription of survivin, cyclin D1, and MDR-1, and the protein expression of slug, vimentin, and N-cadherin, thereby mediating sensitization to GEM. Thus, miR-33a might function as a tumor suppressor to downregulate β-catenin expression, affecting cell growth, apoptosis, the EMT, and GEM resistance.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly human malignant neoplasms [1] . Eighty to eighty-five percent of patients with unresectable pancreatic cancer must undergo chemotherapy because they are often diagnosed at an advanced stage, with distant metastases [2] . PDAC has an extremely poor prognosis, with an overall 5-year survival rate of below 5 %, partly due to poor patient responses to chemotherapeutic agents [3] . Despite many years of research [4, 5] , gemcitabine (GEM) insensitivity remains the main challenge for pancreatic cancer treatment. Thus, improving understanding of the mechanisms underlying GEM resistance to pancreatic cancer will contribute to the development of a novel therapeutic strategy.
MicroRNAs (miRNAs) are a class of single-stranded, small, non-coding RNA molecules that post-transcriptionally silence their target genes and play critical roles as either oncogenes or tumor-suppressor genes [6, 7] . Involvement of miRNAs in pancreatic cancer carcinogenesis, metastasis, and prognosis has been reported [8] . A previous study has shown that miR-33a participates in the transcriptional regulation of genes related to cholesterol biosynthesis and uptake [9] and that it also exhibits antitumor effects in cancer cells. These antitumor effects have been attracting the increasing attention of researchers [10] . miR-33a was first identified as a tumorsuppressive miRNA that is downregulated in cancer cells, affecting their growth and survival by targeting different genes [10, 11] . Interestingly, this miRNA has been modified for delivery in a mouse model of colon carcinoma as cancer therapy, and it is expected to become an efficient and biocompatible means of treatment [12] .
β-Catenin is a member of the Wnt signaling pathway that is aberrantly activated and plays important roles in the pathogeneses of several types of cancers [13, 14] . Wnt signaling inactivates a destruction complex that contains the scaffold protein axin, APC, casein kinase 1 (CK1), and glycogen synthase kinase 3β (GSK-3β), leading to the stabilization and accumulation of cytoplasmic β-catenin [15, 16] . Then, β-catenin enters the nucleus and binds to the TCF/LEF transcription factor, which activates the transcription of genes involved in cell survival and tumor metastasis [17] . This protein also plays a key role in the epithelial-to-mesenchymal transition (EMT), promoting the invasion and migration of cancer cells [18] . The EMT has been demonstrated to be closely associated with drug resistance [19, 20] , and accordingly, β-catenin has recently been reported to be involved in the chemosensitivity of cancer cells [21, 22] , including GEM resistance in pancreatic cancer [23] .
Herein, miR-33a overexpression significantly repressed β-catenin expression and nuclear translocation. The failure of β-catenin to accumulate in the nucleus as a transcriptional cofactor resulted in decreased expression of P-glycoprotein (Pgp), cyclin D1, and survivin and the protein expression of slug, vimentin, and N-cadherin, ultimately enhancing chemosensitivity to GEM. Overall, our results demonstrate additional roles of miR-33a in PDAC and help to validate β-catenin as an important modulator of chemoresistance in pancreatic cancer. This work provides a potential new horizon for targeted therapeutics for GEM-refractory pancreatic cancer.
Materials and methods

Cell culture
Human pancreatic carcinoma cells, SW1990 and MiaPaCa-2, and human embryonic kidney (HEK) 293 T cells were purchased from the American Type Culture Collection (ATCC). SW1990 and HEK293T cells were cultured in DMEM (Biosera, Inc., Loire Valley, France), and MiaPaCa-2 cells were maintained in RPMI 1640 (Biosera). All media were supplemented with 10 % fetal bovine serum (FBS; Biosera), and cells were cultured at 5 % CO 2 and 37°C. All cell lines were authenticated by short tandem repeat (STR) and amelogenin DNA profiling (Beijing Microread Genetics Co., Ltd.).
Quantitative real-time RT-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) and was subsequently reverse transcribed into cDNA to perform realtime PCR with SYBR® Premix Ex Taq™ II (Takara Biotechnology Co., Ltd., Dalian, China). Relative expression of the target genes was analyzed by the ΔΔCt method.
Western blot
Western blotting was performed as described previously [24] . In some experiments, nuclear and cytoplasmic proteins were extracted using a Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime), according to the manufacturer's protocol. Western blotting was performed using the following antibodies: rabbit monoclonal non-phospho-β-catenin (Cell Signaling Technology, 1:1000 dilution), mouse monoclonal MDR-1 (Santa Cruz Biotechnology, 1:100), rabbit monoclonal survivin (Cell Signaling Technology, 1:1000), mouse monoclonal cyclin D1 (Cell Signaling Technology, 1:1000), rabbit monoclonal histone H3 (Abcam, 1:1000), rabbit monoclonal vimentin (GeneTex, 1:10000), rabbit monoclonal slug (Abgent), rabbit monoclonal N-cadherin (Proteintech, 1:1000), and rabbit monoclonal β-actin (Sigma, St. Louis, MO, 1:5000). The expression levels of β-catenin and β-actin were quantified using NIH ImageJ software. The β-catenin/β-actin ratios were calculated for each cell line.
Plate colony formation assay
To examine the effect of miR-33a on clonogenicity, we performed a plate colony formation assay. Cells were seeded in six-well plates in triplicate in their respective normal media at an initial density of 500 cells/well. After 10-14 days, colonies were clearly visible, and cells were fixed with 4 % paraformaldehyde for 15 min at room temperature and stained with 4 mg/ml crystal violet (Sigma). Colonies containing more than 50 cells were counted by light microscopy, and the average number of colonies was determined from three independent experiments. The colony formation rate was calculated by comparing the average number of colonies with the seeded cell numbers.
TUNEL assay for apoptosis
To examine the effect of miR-33a on apoptosis, we performed terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. Cells were cultured in six-well plates on coverslips at a density of 1×10 5 cells per well. Apoptosis was measured using the TUNEL method with an in situ Cell Death Detection Kit (Roche) according to the manufacturer's instructions. Lastly, coverslips were mounted on microscope slides in DAPI Fluoromount-G containing 4′,6-diamidino-2-phenylindole (DAPI; Southern Biotech), and the samples were analyzed by fluorescence microscopy.
Dual luciferase reporter assay
To confirm that β-catenin was a target gene of miR-33a in pancreatic cancer cells, we performed a dual luciferase reporter assay. Cells were seeded into 96-well plates at a density of approximately 1.5×10 4 cells/well and were co-transfected with miRNA mimics and a luciferase reporter construct using Lipofectamine 2000 reagent (Life Technologies). The cells were lysed in passive lysis buffer at 48 h after transfection. Renilla and firefly luciferase activities were quantified using a Dual Luciferase Assay System (Promega).
Immunofluorescence analysis
To assess the subcellular redistribution of β-catenin, we performed immunofluorescence analysis. MiaPaCa-2 cells were cultured in six-well plates on coverslips at a density of 1×10 5 cells per well and were then washed and fixed with 4 % paraformaldehyde. Next, the cells were hybridized with a rabbit monoclonal non-phospho-β-catenin antibody (Cell Signaling Technology, 1:100). After incubation with an Alexa Fluor 488-conjugated goat antirabbit IgG antibody, coverslips were mounted on microscope slides in DAPI Fluoromount-G (Southern Biotech), and immunofluorescence was visualized by fluorescence microscopy.
Statistical analysis
The t test (two samples) and one-way analysis of variance (ANOVA) (multiple comparisons) were performed for group comparisons of normally distributed data. The non-parametric Wilcoxon test was conducted to assess continuous nonnormally distributed data. The Tukey-Kramer honestly significant difference (HSD) test was applied for multiple comparisons, following paired comparisons performed by ANOVA. Statistical significance was set at a P<0.05 (two-tailed).
Results miR-33a targets the 3′UTR of β-catenin in human pancreatic cancer cells Consistent with a previous report [11] , miR-33a expression was downregulated in PDAC (unpublished data). Given that β-catenin is a target gene of miR-33a in hepatocellular carcinoma cells [25] , we examined whether its expression is regulated by miR-33a in human pancreatic cancer cells. The results showed that the stable overexpression of miR-33a decreased the expression of β-catenin not only at the protein level but also at the messenger RNA (mRNA) level (Fig. 1a) . We next predicted the putative miR-33a target sites in the 3′UTR of β-catenin by performing bioinformatics analysis (PicTar). The 3′ UTR of β-catenin transcript variant 1 (NM_001904), including the remaining two Homo sapiens transcript variants, was chosen as the full-length 3′UTR. Two highly conserved putative target sites were present in the 3′UTRs of all three variants (Fig. 1b) , and the sites were mutated to establish β-catenin Δ 3′UTR constructs (Δ 3′UTR, Δ 3′UTR#1, and Δ 3′UTR#2) (Fig. 1c) . Co-transfection of HEK293T cells or MiaPaCa-2 cells with miR-33a mimics repressed the luciferase activity of the wild-type β-catenin 3′UTR construct but not that of an empty psiCHECK-2 vector (Fig. 1d) . Moreover, the luciferase activity of the wild-type β-catenin 3′UTR construct was not repressed by co-transfection of cells with cel-miR-239b mimics (Fig. 1d) . Further, luciferase activity was greatly decreased following co-transfection of miR-33a mimics with β-catenin Δ 3′UTR#2 and was marginally decreased following co-transfection of mimics with β-catenin Δ 3′UTR#1 or Δ 3′ UTR with both putative target sites mutated (Fig. 1d) . Thus, β-catenin suppression is dependent upon miR-33a, especially miR-33a-binding site #1.
miR-33a acts as a tumor suppressor in human pancreatic cancer cells miR-33a has been reported to be a tumor suppressor gene [11] . The inhibition of MiaPaCa-2 and SW1990 cell proliferation by miR-33a was validated by plate colony formation assays (Fig. 2a, b) . Moreover, the stable expression of miR-33a resulted in a markedly higher ratio of apoptotic cells in both of the cell lines (Fig. 2c) . Similar results were observed using TUNEL immunofluorescence staining. Additionally, miR33a induced apoptosis in human pancreatic cancer cells (Fig. 2d) .
miR-33a and β-catenin are involved in GEM resistance in human pancreatic cancer cells
Our previous study has demonstrated that miR-33a overexpression enhances chemosensitivity to GEM via repression of Pim-3 expression (unpublished data). In this study, we observed that GEM treatment reduced miR-33a expression in a dose-dependent manner (Fig. 3a) . Concomitantly, this treatment dose-dependently enhanced β-catenin protein and mRNA expression (Fig. 3b) . This increase in β-catenin expression was further confirmed in GEM-resistant cells, in which its expression was also enhanced compared with that in parental cells (Fig. 3c) ; however, this upregulation of β-catenin expression was significantly inhibited upon stable transfection of miR-33a into these cells (Fig. 3c) . β-Catenin signaling is a component of the Wnt signaling pathway, which is involved in the EMT [18] . Consistent with a previous report, we observed that GEM-resistant MiaPaCa-2 res cells with a low level of miR-33a expression and high level of β-catenin expression had altered spindle-shaped morphologies, similar to what was observed by microscopy during the EMT (Fig. 3d) ; however, the overall morphology of SW1990 res cells was minimally affected. Moreover, the morphological changes could be moderately counteracted by miR-33a expression in MiaPaCa-2 res cells, but not in SW1990 res cells (Fig. 3d) .
miR-33a represses the translocation of β-catenin and transcription of its downstream genes
Inhibition of β-catenin expression by miR-33a was accompanied by its subcellular redistribution, including a decrease in its nuclear localization (Fig. 4a-c) . Because β-catenin translocates to the nucleus to act as a transcriptional co-factor, we hypothesized that the miR-33a-mediated downregulation of β-catenin inhibits downstream genes that are important to drug resistance. We next evaluated the expression of survivin, cyclin D1, and MDR-1. The stable expression of miR-33a led to repression of β-catenin expression and blockage of the transcription and translation of the analyzed genes (Fig. 4d, e) . Moreover, miR-33a inhibited the expression of slug, vimentin, and N-cadherin, markers of the mesenchymal phenotype (Fig. 4f) .
Discussion
miRNA-33 has two isoforms, miR-33a and miR-33b, which are involved in the transcriptional regulation of genes associated with cholesterol biosynthesis and uptake [9] . miR-33b has not been previously implicated in tumor progression, while miR-33a has been attracting recent attention in this regard. In non-neoplastic cells, miR-33a is considered a potential therapeutic target for the mitigation of metabolic diseases based on its effects on regulating lipid metabolism and insulin secretion [9, 26, 27] . In cancer cells, however, it has different target genes than those in non-neoplastic cells, acting as a tumor suppressor to repress genes that are important to cell growth and survival, such as β-catenin, c-myc, CDK6, and Pim-1 [10, 11, 28, 25] . In addition, Thomas et al. have determined that miR-33a is expressed as a tumor suppressor at comparably low levels in liver carcinoma, leukemia, and colon cancer cell lines [11] . In our study, miR-33a had an antitumor effect on pancreatic cancer and was further downregulated in a dose-dependent manner upon GEM treatment. Thus, determining the causes of miR-33a downregulation to recover its expression is a critical step for the treatment of GEM resistance in pancreatic cancer. Reportedly, XB130, a newly discovered adaptor protein, represses miR-33a expression in cancer cells [28] and is associated with the prognosis and chemosensitivity of gastric cancer [29] . Future studies should be conducted to determine whether XB130 regulates miR-33a to induce GEM resistance in pancreatic cancer.
Resistance to chemotherapeutic drugs ubiquitously occurs in cancer therapy and is a major reason for treatment failure in cancer patients. In our study, β-catenin was found to be involved in GEM resistance in pancreatic cancer. This result is consistent with the findings of other studies [23] . Interestingly, Wnt/β-catenin signaling also affects sensitivities to doxorubicin, etoposide, paclitaxel, and cisplatin in neuroblastoma cells [21] . β-Catenin upregulates cyclin D1 to advance the cell cycle and promotes survivin protein expression to inhibit apoptosis [17] , increasing the threshold for drug-induced apoptosis. In line with these findings, we observed that miR-33a overexpression repressed the β-catenin-mediated expression of survivin, cyclin D1, and MDR-1 at the mRNA and protein levels.
The EMT is induced in pancreatic cancer in part via the Wnt/β-catenin pathway [18] , and cancer cells with the mesenchymal phenotype tend to be resistant to chemotherapy [19, 20] . In our study, MiaPaCa-2 res cells adopted spindle-shaped morphologies similar to their morphologies during the EMT, whereas their morphologies were restored to those of parental cells and GEM sensitivity was increased when β-catenin was downregulated. Therefore, miR-33a-mediated GEM resistance might be partly due to inhibition of the EMT. More studies are needed to elucidate this hypothesis, although β-catenin could induce the EMT [18] , and miR-33a has been reported to downregulate TWIST, a marker of the mesenchymal phenotype [30] . Thus, β-catenin is an important gene involved in induction of chemotherapy resistance via a variety of mechanisms, and it may also play a role in GEM resistance in pancreatic cancer.
Considering the various effects of β-catenin, miRNAs that regulate this protein have attracted increasing attention in the study of cancer pathophysiology. miR-33a decreases AKT Fig. 3 miR-33a and β-catenin are involved in gemcitabine resistance in human pancreatic cancer cells. a Gemcitabine treatments decreased miR33a expression in a dose-dependent manner. The data are presented as the mean ± SEM of three independent experiments. *P<0.05 and **P<0.01 versus parental cells. b Gemcitabine treatment increased β-catenin mRNA (top panels) and protein (bottom panels) expression in dosedependent manners. The data are presented as the mean±SEM of three independent experiments. **P<0.01 versus gemcitabine-resistant cells. c Analyses of β-catenin mRNA (top panels) and protein expression (bottom panels) in resistant cells with or without stable expression of exogenous miR-33a. The data are presented as the mean ± SEM of three independent experiments. *P < 0.05 and **P < 0.01 versus gemcitabine-resistant cells. d Morphological changes of gemcitabineresistant cells with or without stable expression of exogenous miR-33a. The cells were photographed under×200 original magnification, and the inset in each panel is×400 original magnification phosphorylation, which is an important upstream molecule that regulates the stabilization of cytoplasmic β-catenin [27, 31] . Thus, regulation of β-catenin protein expression by miR33a is partly accomplished by the direct inhibition of its translation. Additionally, we have found that miR-33a blocks β-catenin accumulation by targeting Pim-3 kinase (unpublished Fig. 4 miR-33a blocks the translocation of β-catenin and expression of its downstream genes to increase gemcitabine sensitivity. a Both cytosolic and nuclear fractions were extracted to performed Western blot analysis using the indicated antibodies. Histone H3 and β-actin were used as purity controls. b Fluorescence microscopy analysis (left panel) of the subcellular distribution of β-catenin. DAPI was used to detect nuclei. c Quantification of cells with nuclear β-catenin. The average cell numbers were counted from five independent areas. The data are presented as the mean ± SEM of three independent experiments. **P<0.01 versus parental cells. d The expression levels of β-catenin, cyclin D1, survivin, and MDR-1 in MiaPaCa-2 and SW1990 cells were decreased by miR-33a, as assessed by qRT-PCR. The data are presented as the mean ± SEM of three independent experiments. *P<0.05 and **P<0.01 versus MiaPaCa-2 or SW1990 parental cells. e Western blot analysis of MiaPaCa-2 and SW1990 cells stably expressing miR-33a and the corresponding parental cells using the indicated antibodies. f Western blot analysis of markers of the mesenchymal phenotype in MiaPaCa-2 and SW1990 cells stably expressing miR-33a and the corresponding parental cells Fig. 5 Presumed mechanism of miRNA-33a-mediated regulation of β-catenin expression and nuclear translocation in human pancreatic cancer cells data). Thus, this miRNA regulates β-catenin expression by directly inhibiting its transcription and indirectly affecting its cytosolic stabilization via the Pim-3/AKT/GSK-3β axis, eventually leading to a decrease in nuclear translocation (Fig. 5) .
Taken together, β-catenin is an important molecule for GEM resistance. We have determined that GEM enhances β-catenin expression, which promotes the EMT and eventually induces chemoresistance, while miR-33a represses β-catenin expression in pancreatic cancer. Simultaneously, our findings have enriched knowledge of the biological function of miR-33a, which not only affects cell survival, proliferation, and migration but also decreases GEM efflux, eventually leading to increased chemosensitivity to GEM. These results contribute to knowledge of the relationship between metabolism and carcinogenesis. Therefore, this work could contribute to the development of a novel biocompatible strategy for miRNA replacement therapy to target β-catenin in chemotherapy-resistant pancreatic cancer. 
